Enanta Pharmaceuticals (ENTA) Assets (2012 - 2026)

Enanta Pharmaceuticals has reported Assets for 15 years, with the latest figure at $314.7 million in Q1 2026.

• For the quarter ending Q1 2026, Assets fell 2.57% year-over-year to $314.7 million; the trailing twelve-month figure through Mar 2026 stood at $314.7 million (down 2.57% YoY), and the FY2025 full-year result was $280.7 million, down 25.47% from the prior year.
• Assets for Q1 2026 stood at $314.7 million, down from $329.5 million in the prior quarter.
• The five-year high for Assets was $495.2 million in Q2 2023, with the low at $280.7 million in Q3 2025.
• Historically, Assets has averaged $371.4 million across 5 years, with a median of $375.4 million in 2022.
• Annual changes were most pronounced in 2023 — Assets climbed 28.54% — and 2025, when it retreated 25.47%.
• Enanta Pharmaceuticals' Assets stood at $347.5 million in 2022, then advanced by 23.3% to $428.5 million in 2023, then retreated by 18.64% to $348.6 million in 2024, then decreased by 5.49% to $329.5 million in 2025, then fell by 4.49% to $314.7 million in 2026.
• The last three Assets figures came in at $314.7 million (Q1 2026), $329.5 million (Q4 2025), and $280.7 million (Q3 2025), per Business Quant data.